Phathom Pharmaceuticals (PHAT) Cash from Operations Growth (5y) (2023 - 2026)

Phathom Pharmaceuticals (PHAT) Cash from Operations Growth (5y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,861.65 Bn 66,861.36 Bn -
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn -
3 Akari Therapeutics 1,071.19 Bn 1,071.19 Bn -
4 BeOne Medicines 469.11 Bn 464.32 Bn 1.35 Bn
5 Vertex Pharmaceuticals 123.03 Bn 115.78 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.13 Bn 61.37 Bn 3.31 Bn
7 Belite Bio 63.44 Bn 63.44 Bn -
8 Argenx Se 55.97 Bn 50.78 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.53 Bn 34.52 Bn 959.66 Mn
10 Phathom Pharmaceuticals 974.75 Mn 790.99 Mn 46.31 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 20.66%
Dec 31, 2025 29.24%
Sep 30, 2025 7.40%
Jun 30, 2025 -46.35%
Mar 31, 2025 -49.38%
Dec 31, 2024 -22.10%
Sep 30, 2024 -54.99%
Jun 30, 2024 -68.47%
Mar 31, 2024 -143.46%
Dec 31, 2023 -170.57%